UBR5: The Potential Drug Target and Biomarker (G51366)

Target Name: UBR5

NCBI ID: G51366

UBR5

UBR5: The Potential Drug Target and Biomarker

Uncovering new drug targets and biomarkers is a critical aspect of drug development. Drug targets are molecules that are responsible for specific biological processes and are targeted by drugs to induce a response. Biomarkers are molecules that are associated with a specific disease or condition and can be used to monitor the progression of the disease. In this article, we will discuss UBR5, an E3 identified by differential display, which may serve as a potential drug target or biomarker.

The E3 protein family is a subset of the superfamily of Eukaryotic translation initiation factors (STIF), which are involved in the process of translation of mRNA into protein. UBR5 is one of the E3 proteins that has been identified using differential display technology.

Differential display technology is a technique that allows researchers to identify potential drug targets by analyzing large datasets of gene expression data. In this technique, researchers first generate a large library of RNAi-converted cDNA library, which is used to express the gene of interest in a cell-free format. The libraries are then used to enrich for the gene of interest using affinity purification protocols. The enriched fractions are then sequenced to identify new differential expressed genes (DEGs), which are associated with the protein of interest.

The UBR5 protein

UBR5 is a 21 kDa protein that is expressed in various tissues and cells, including muscle, liver, and kidney. It is composed of 116 amino acid residues and has a calculated pI of 4.94. UBR5 is involved in various cellular processes, including cell signaling, DNA replication, and metabolism.

The differential display data

Differential display technology has been used to identify several potential drug targets based on UBR5 expression. One of the most promising targets is the protein p180, which is a G protein-coupled receptor (GPCR) that is involved in insulin signaling and metabolism. UBR5 was found to be highly expressed in muscle tissue and was shown to interact with p180. This interaction may suggest a potential role for UBR5 as a drug target for insulin-related diseases.

Another potential drug target is the protein FKBP1, which is a protein that is involved in protein-protein interactions and is expressed in various tissues. UBR5 was found to be highly expressed in liver and kidney tissue and to interact with FKBP1. This interaction may suggest a potential role for UBR5 as a drug target for diseases associated with protein-protein interactions.

The potential implications of UBR5 as a drug target

The identification of UBR5 as a potential drug target based on differential display technology is an exciting development in the field of drug development. If UBR5 is indeed a valid drug target, it may lead to the development of new treatments for various diseases.

One of the potential benefits of targeting UBR5 is its involvement in various cellular processes that are important for normal cellular function. This may make it an attractive target for drugs that are designed to modulate these processes. For example, if UBR5 is involved in cell signaling, targeting it with a drug that inhibits signaling pathways may be an effective way to treat various diseases.

Another potential benefit of targeting UBR5 is its involvement in protein-protein interactions. Many diseases are caused by protein-protein interactions that go wrong. Targeting UBR5 with a drug that modulates protein-protein interactions may be an effective way to treat various diseases.

The future of UBR5 research

The discovery of UBR5 as a potential drug target based on differential display technology is an exciting development in the field of drug development. Further research is needed to determine the exact role of UBR5 in various cellular processes and to identify small molecules that can modulate its activity.

If UBR5 is indeed a valid drug target, it may lead to the development of new treatments for various diseases. Further research is needed to

Protein Name: Ubiquitin Protein Ligase E3 Component N-recognin 5

Functions: E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation (By similarity). Involved in maturation and/or transcriptional regulation of mRNA by activating CDK9 by polyubiquitination. May play a role in control of cell cycle progression. May have tumor suppressor function. Regulates DNA topoisomerase II binding protein (TopBP1) in the DNA damage response. Plays an essential role in extraembryonic development. Ubiquitinates acetylated PCK1. Also acts as a regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes

The "UBR5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBR5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets